Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

Your bedroom lighting choices could be silently damaging your health every night. Research shows just one night of moderate light exposure during sleep raises insulin resistance and prevents proper ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

Baxdrostat is an investigational highly selective, oral, small molecule designed to inhibit aldosterone synthase.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

Other standout performers included cycling, which had stronger effects than walking in both pressure types. Walking, though ...